Literature DB >> 22387143

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.

Mark L Metersky1, Robert G Masterton, Hartmut Lode, Thomas M File, Timothy Babinchak.   

Abstract

Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387143     DOI: 10.1016/j.ijid.2012.01.003

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  79 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

2.  Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection.

Authors:  Keer Sun; Dennis W Metzger
Journal:  J Immunol       Date:  2014-02-21       Impact factor: 5.422

3.  Why is coinfection with influenza virus and bacteria so difficult to control?

Authors:  Linda S Cauley; Anthony T Vella
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

4.  Evaluation of Unbiased Next-Generation Sequencing of RNA (RNA-seq) as a Diagnostic Method in Influenza Virus-Positive Respiratory Samples.

Authors:  Nicole Fischer; Daniela Indenbirken; Thomas Meyer; Marc Lütgehetmann; Heinrich Lellek; Michael Spohn; Martin Aepfelbacher; Malik Alawi; Adam Grundhoff
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

Review 5.  Effects of influenza immunization on pneumonia in the elderly.

Authors:  Jung Yeon Heo; Joon Young Song; Ji Yun Noh; Min Joo Choi; Jin Gu Yoon; Saem Na Lee; Hee Jin Cheong; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2017-12-19       Impact factor: 3.452

6.  Investigating the Extremes of Antibiotic Use with an Epidemiologic Framework.

Authors:  Marc H Scheetz; Page E Crew; Cristina Miglis; Elise M Gilbert; Sarah H Sutton; J Nick O'Donnell; Michael Postelnick; Teresa Zembower; Nathaniel J Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  Heterogeneity in Estimates of the Impact of Influenza on Population Mortality: A Systematic Review.

Authors:  Li Li; Jessica Y Wong; Peng Wu; Helen S Bond; Eric H Y Lau; Sheena G Sullivan; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2018-02-01       Impact factor: 4.897

8.  Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection.

Authors:  Katrin Reppe; Peter Radünzel; Kristina Dietert; Thomas Tschernig; Thorsten Wolff; Sven Hammerschmidt; Achim D Gruber; Norbert Suttorp; Martin Witzenrath
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

Review 9.  Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.

Authors:  Ankeet S Bhatt; Adam D DeVore; Adrian F Hernandez; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2017-02-01       Impact factor: 12.035

10.  Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation.

Authors:  Liyen Loh; Zhongfang Wang; Sneha Sant; Marios Koutsakos; Sinthujan Jegaskanda; Alexandra J Corbett; Ligong Liu; David P Fairlie; Jane Crowe; Jamie Rossjohn; Jianqing Xu; Peter C Doherty; James McCluskey; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.